Abstract
Proteasome inhibitors are emerging as effective drugs for the treatment of multiple myeloma and possibly certain subtypes of non-Hodgkin's lymphoma. Bortezomib (Velcade) is the first proteasome inhibitor proven to be clinically useful and will soon be followed by a second generation of small molecule inhibitors with improved pharmacological properties. Although it is now understood that certain types of malignancies have an exquisite dependence on a functional proteasome for their survival, the underlying reason(s) remain unclear as of now. In this context, addiction to nuclear factor-κB (NF-κB)-induced survival signals, activation of the unfolded protein response as well as a reduced proteasomal activity in differentiated plasma cells have all been proposed to justify proteasome inhibitors' activity in susceptible tissues. In addition to their anticancer properties, bortezomib and related drugs modulate inflammatory and immune responses by affecting function and survival of immune cells such as lymphocytes and dendritic cells. The present review offers an overview of the biological effects that have been involved in proteasome inhibitors' antitumor activity and suggests prospective future applications for these drugs based on their recently characterized anti-inflammatory and immunomodulatory effects.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mani A, Gelmann EP . The ubiquitin–proteasome pathway and its role in cancer. J Clin Oncol 2005; 23: 4776–4789.
Adams J . The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349–360.
Adams J . The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5: 417–421.
Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005; 123: 773–786.
Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 2005; 8: 407–419.
Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M et al. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial–mesenchymal transition. Nat Cell Biol 2004; 6: 931–940.
Salceda S, Caro J . Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin–proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997; 272: 22642–22647.
Nakayama KI, Nakayama K . Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006; 6: 369–381.
Brummelkamp TR, Nijman SM, Dirac AM, Bernards R . Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kB. Nature 2003; 424: 797–801.
Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G . The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003; 424: 801–805.
Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G . CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003; 424: 793–796.
Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99: 14374–14379.
Leverkus M, Sprick MR, Wachter T, Mengling T, Baumann B, Serfling E et al. Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. Mol Cell Biol 2003; 23: 777–790.
Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003; 102: 303–310.
Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH . Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA 2003; 100: 9946–9951.
Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D . The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006; 107: 257–264.
Podar K, Shringarpure R, Tai YT, Simoncini M, Sattler M, Ishitsuka K et al. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res 2004; 64: 7500–7506.
Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006; 66: 184–191.
Cenci S, Mezghrani A, Cascio P, Bianchi G, Cerruti F, Fra A et al. Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J 2006; 25: 1104–1113.
Nencioni A, Hua F, Dillon CP, Yokoo R, Scheiermann C, Cardone MH et al. Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood 2005; 105: 3255–3262.
Nencioni A, Wille L, Dal Bello G, Boy D, Cirmena G, Wesselborg S et al. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells. Clin Cancer Res 2005; 11: 4259–4265.
Wagenknecht B, Hermisson M, Groscurth P, Liston P, Krammer PH, Weller M . Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release. J Neurochem 2000; 75: 2288–2297.
Landowski TH, Megli CJ, Nullmeyer KD, Lynch RM, Dorr RT . Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005; 65: 3828–3836.
Smolewski P, Duechler M, Linke A, Cebula B, Grzybowska-Izydorczyk O, Shehata M et al. Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells. Leukemia Res 2006; 18 April [E-pub ahead of print].
Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S . The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 2003; 102: 3765–3774.
Pei XY, Dai Y, Grant S . Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004; 10: 3839–3852.
David E, Sun SY, Waller EK, Chen J, Khuri FR, Lonial S . The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood 2005; 106: 4322–4329.
Dai Y, Rahmani M, Grant S . Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene 2003; 22: 7108–7122.
Nawrocki ST, Carew JS, Dunner Jr K, Boise LH, Chiao PJ, Huang P et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005; 65: 11510–11519.
Nencioni A, Garuti A, Schwarzenberg K, Cirmena G, Dal Bello G, Rocco I et al. Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur J Immunol 2006; 36: 681–689.
Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, Bisht KS et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther 2004; 3: 551–566.
Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006; 107: 1092–1100.
Derouet M, Thomas L, Cross A, Moots RJ, Edwards SW . Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1. J Biol Chem 2004; 279: 26915–26921.
Scagliotti G . Proteasome inhibitors in lung cancer. Crit Rev Oncol Hematol 2006; 58: 177–189.
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617.
Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165–172.
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498.
Musto P, Falcone A, Sanpaolo G, Guglielmelli T, Zambello R, Balleari E et al. Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. Leukemia Res 2006; 30: 283–285.
Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058–3065.
Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006; 24: 937–944.
Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776–783.
Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 755–762.
O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676–684.
Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667–675.
Younes A, Pro B, Fayad L . Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood 2006; 107: 1731–1732.
Voorhees PM, Orlowski RZ . The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 2006; 46: 189–213.
Richardson PG, Mitsiades C, Hideshima T, Anderson KC . Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 2006; 57: 33–47.
Wu J . On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants. Am J Transplant 2002; 2: 904–912.
Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS et al. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 1998; 95: 15671–15676.
Zollner TM, Podda M, Pien C, Elliott PJ, Kaufmann R, Boehncke WH . Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J Clin Invest 2002; 109: 671–679.
Vanderlugt CL, Rahbe SM, Elliott PJ, Dal Canto MC, Miller SD . Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J Autoimmun 2000; 14: 205–211.
Luo H, Wu Y, Qi S, Wan X, Chen H, Wu J . A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 2001; 72: 196–202.
Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004; 101: 8120–8125.
Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR . NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood 2006; 107: 827–834.
Sun K, Wilkins DE, Anver MR, Sayers TJ, Panoskaltsis-Mortari A, Blazar BR et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood 2005; 106: 3293–3299.
Blanco B, Perez-Simon JA, Sanchez-Abarca LI, Carvajal-Vergara X, Mateos J, Vidriales B et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006; 107: 3575–3583.
Lanzavecchia A, Sallusto F . Regulation of T cell immunity by dendritic cells. Cell 2001; 106: 263–266.
Bayry J, Thirion M, Delignat S, Misra N, Lacroix-Desmazes S, Kazatchkine MD et al. Dendritic cells and autoimmunity. Autoimmun Rev 2004; 3: 183–187.
Chen M, Wang YH, Wang Y, Huang L, Sandoval H, Liu YJ et al. Dendritic cell apoptosis in the maintenance of immune tolerance. Science 2006; 311: 1160–1164.
Nencioni A, Schwarzenberg K, Brauer KM, Schmidt SM, Ballestrero A, Grunebach F et al. The proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood 2006; 108: 551–558.
Chromik J, Schnurer E, Georg Meyer R, Wehler T, Tuting T, Wolfel T et al. Proteasome-inhibited dendritic cells demonstrate improved presentation of exogenous synthetic and natural HLA-class I peptide epitopes. J Immunol Methods 2006; 308: 77–89.
Wong C, Morse M, Nair SK . Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides. J Immunother 1998; 21 (1): 32–40.
Phillips JB, Williams AJ, Adams J, Elliott PJ, Tortella FC . Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. Stroke 2000; 31: 1686–1693.
Di Napoli M, McLaughlin B . The ubiquitin–proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors. Curr Opin Invest Drugs 2005; 6: 686–699.
Kukan M . Emerging roles of proteasomes in ischemia-reperfusion injury of organs. J Physiol Pharmacol 2004; 55: 3–15.
Kaelin Jr WG . The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5: 689–698.
Acknowledgements
This work was supported by a grant from Deutsche Forschungsgemeinschaft (SFB685). AN, FP and AB are supported by the University of Genova.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nencioni, A., Grünebach, F., Patrone, F. et al. Proteasome inhibitors: antitumor effects and beyond. Leukemia 21, 30–36 (2007). https://doi.org/10.1038/sj.leu.2404444
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404444
Keywords
This article is cited by
-
Novel immunotherapies in multiple myeloma
International Journal of Hematology (2022)
-
Protein clearance strategies for disease intervention
Journal of Neural Transmission (2022)
-
Autophagy protects HUVECs against ER stress-mediated apoptosis under simulated microgravity
Apoptosis (2019)
-
Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide
Investigational New Drugs (2018)
-
Positioning of proteasome inhibitors in therapy of solid malignancies
Cancer Chemotherapy and Pharmacology (2018)